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ABSTRACT
Two new potential magnetic resonance imaging contrast agents, Gd-hematoporphyrin (Gd-H) and
Gd-tetra-carboranylmethoxyphenyl-porphyrin (Gd-TCP), were synthesized and applied to nude mice
with human melanoma (MM-138) xenografts. These agents showed a high relaxivity because of their
greater potential to coordinate water molecules. The reduction of T1 relaxation times of 16 and 21%
was observed in human melanoma tumors grafted in the nude mice 24 h after injection of Gd-TCP
andGd-H, respectively. The percent of injected Gd, that localized to the tumor and measured by
inductively coupled plasma atomic emission spectroscopy (ICP-AES), was approximately 21% for Gd-
TCP and 28% for Gd-H. A higher concentration of Gd was achieved compared with control indicating
selective delivery of Gd-porphyrins to the melanoma xenografts. The data indicate that Gd-TCP can
be used as a dual probe for diagnosis in MR imaging and for therapy in boron neutron capture
therapy (BNCT). Iran. Biomed. J. 5 (2 & 3): 87-95, 2001
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INTRODUCTION
he use of contrast agents to shortening
relaxation times following enhanced signal
intensity may extend the potential of
magnetic resonance (MR) imaging to diagnosis of
tumors in the early stages. Paramagnetic chelates
using the endogenous porphyrin ring as the
chelating agents are a promising and interesting
family group of potential MR imaging contrast
agents [1]. Gd-porphyrins have been synthesized
and are currently being investigated [2-4] and
shown selective affinity for a variety of tumors [5].
By choosing gadolinium as the metal for
incorporation into the carboranylmethoxyphenyl-
porphyrin (TCP) and hematoporphyrin, they can be
used simultaneously as MR imaging contrast
agents. For this reason, two new gadolinium
complexes of porphyrins were synthesized. The
synthetic porphyrin, 1, 6, 11, 16-tetra (3-o-
carboranylmethoxy) phenyl-porphyrin was
produced by modification of the method of Miura
et al. [6] and was inserted with Gd to yield Gd-
tetra-carboranylmethoxyphenyl-porphyrin (Gd-
TCP). The naturally occurring porphyrin,
hematoporphyrin IX was also inserted with Gd to
yield GD-hematoporphyrin (Gd-H).
The porphyrins offer a stable chelate for the
transportation of paramagnetic metals into the
tumors and by attachment they could destroy the
cancer cells. The synthetic porphyrin TCP is an
example of this concept where boron atoms have
been attached chemically to the porphyrin, thus
offering the potential for boron neutron capture
therapy (BNCT). The gadolinium complex of these
two porphyrins is unknown and in this work the
synthesis of these MR imaging contrast agents are
investigated.
An animal study was performed for developing
radiopharmaceuticals and pharmacokinetics of these
contrast agents. In the present study, Gd-
hematoporphyrin (Gd- [18, 13-bis (hydroxyethyl)-3,
7, 12, 17-tetramethyl-21H, 23 H porphin-2, 18-
dipropionic acid]) and Gd-TCP (Gadolinium-tetra-
carboranylmethoxyphenyl-porphyrin) were targeted
into the nude mice model with a human melanoma
(MM-138) xenograft [7]. The bio-distribution, the
T1 relaxation times, and the signal enhancement of
the contrast agents are presented and the results are
compared. The gadolinium concentration of tissues
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was determined using an acid digestion method [8]
by Inductivity Coupled Plasma Atomic Emission
Spectroscopy (ICP-AES).
MATERIALS AND METHODS
Gd-H.Gadolinium (III) nitrate hexa-hydrate(0.30
g, 0.66 mmol) was dissolved in 2 ml of distilled
water. Hematoporphyrin ([8, 13-bis (1-hydroxy-
ethyl)-3, 7, 12, 17-tetramethyl-21H, 23H-porphine-
2, 18-dipropionic acid]) (Sigma, Aldrich) powder
(0.40 g, 0.66 mmol) was suspended in 2 ml of
distilled water, added to the gadolinium solution
and refluxed until the solution become
homogeneous. The solution was allowed to cool at
room temperature and then was concentrated to 1
ml under reduced pressure by heating. The resulting
white solid was filtered, washed carefully with ice-
cold water (2  0.5 ml) and dried in the oven at
80ºC. The yield was 0.11 g (21%).
Gd-TCP. The experimental procedure for the
synthesis of this new MR imaging contrast agent is
as follows:
The synthesis of this compound involved the
preparation of the known porphyrin,
tetra-carboranylmethoxyphenyl-porphyrin (TCP-
H2) followed by insertion of the gadolinium ion into
this porphyrin. The first part of this synthesis
involved the formation of an aldehyde containing
the o-carborane group. This aldehyde was reacted
with pyrrole to form the porphyrin, TCP-H2. The
gadolinium ion was inserted into TCP-H2 by
adaptation of Miura’s method [6] for the nickel
complex. The synthetic route for the production of
Gd-TCP is shown in Figure 1. The purity and
identity of each compound was confirmed by low-
resolution mass spectroscopy, LRMS (Shimatzu
QP5000/GC17A), and NMR analysis, both of them
are previously discussed.
(3-(o-carboranylmethoxy)phenyl)methanol. (3-
(o-carboranylmethoxy)phenyl)-methyl ethanoate
(5.2 g, 24.5 mmol) was refluxed in a 1:80 (v/v)
conc. HCl: MeOH (80 ml) at 60C for 1 hour. The
solvent was removed under reduced pressure
yielding a crimson solid. The yield was 5.8 g (85%).
MS (molecular ion, m/z (peak intensity)
Observed. 276.30 (2.3); 277.30 (9.1); 278.30
(28.9); 279.30 (65.8); 280.30 (100.0); 281.30
(93.8); 282.30 (43.4); 283.30 (4.8).
Calculated. 276.26 (1.6); 277.26 (8.0); 278.25
(27.3); 279.25 (64.2); 280.25 (100.0); 281.24
(94.3); 282.24 (43.3); 283.24 (3.7).
1H NMR (CDCl3).  ppm 6.90 (d, 1H, J(HH)2.1Hz,
ArH); 7.00 (d, 1H, J(HH)7.4 Hz, ArH); 7.30 (t, 1H,
J(HH)7.4 Hz, ArH); 6.75 (dd, 1H, J(HH)7.4, 2.1 Hz,
ArH); 4.70 (s, 2H, B10H11C2CH2O-Ar); 4.40 (s, 2H,
Ar-CH2OH); 4.10 (br s, 1H, carborane CH); 1.5-3.3
(br m, 10H, B10H10).
13C NMR (CDCl3). ppm 64.7 (Ar-CH2OH);
142.9, 157.3 (ArCR); 129. 9, 120.8, 113.8, 112.9
(ArCH); 69.1 (B10H11C2CH2O-Ar); 57.8 (RCH,
carborane); 71.3 (CR, carborane).
11B (CDCl3).ppm 51.7, 49.9, 45.5, 42.9, 41.6.
3-o-carboranylmethoxybenzaldehyde. (3-(o-
carboranylmethoxy)phenyl)- methanol (7.8 g, 27.7
mmol) was added to pyridiniumchlorochromate (9.0
g, 41.6 mmol) in dichloromethane (62 ml) at 0C
and was stirred for 2.5 hours. The combined
solution was washed with water (50 ml  3) and
then extracted with dichloromethane (50 ml  3).
The combined extracts were dried with anhydrous
sodium sulfate and the solvent was removed under
reduced pressure. The resulting compound was
purified using flash chromatography (silica, gel
CH2Cl2 eluent) to give 6.2 g (80%) of a crimson
crystalline solid.
MS (molecular ion, m/z (peak intensity)
Observed. 275.25 (3.1); 276.30 (10.7); 277.30
(21.1); 278.30 (30.4); 279.30 (29.0); 280.30 (13.6);
281.40 (1.7).
Calculated. 275.24 (2.4); 276.24 (8.3); 277.23
(19.5); 278.23 (30.4); 279.23 (28.7); 280.22 (13.2);
281.22 (1.1).
1H NMR (CDCl3).  ppm 9.90 (s, 1H, CHO); 7.35
(dd, 1H, J(HH) 1.1, 2.5 Hz, ArH); 7.14 (dt, 1H,
J(HH)7.7, 2.6 Hz, ArH); 7.48 (t, 1H, J(HH)7.7 Hz,
ArH); 7.53 (ddd, 1H, J(HH)7.7, 2.6, 1.1 Hz, ArH);
4.50 (s, 2H, B10H11C2CH2O-Ar); 4.10 (s, 1H,
carborane CH); 1.5-3.3 (br m, 10H, B10H10).
13C NMR (CDCl3). ppm 191.4 (Ar-CHO); 137.9,
157.5 (ArC-); 130.6, 125.5, 121.8, 112.5 (ArC-H);
69.3 (B10H11C2CH2O-Ar); 57.8 (RCH, carborane);
71.3 (CR, carborane).
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11B (CDCl3). ppm 51.9, 50.0, 45.6, 42.9, 41.5.
1, 6, 11, 16-tetra-[3-(carboranylmethoxy)
phenyl]–porphyrin. 3-o-carboranyl- methoxy-
benzaldehyde (4.2 g, 15 mmol) and pyrrole (1.04
ml, 15.0 mmol) were added to 1 L of distilled
CH2Cl2 in a 2 L, three-neck, round-bottomed flask
fitted with a reflux condenser and nitrogen inlet
port, and stirred magnetically at room temperature.
After 15 minutes, BF3etherate (0.4 ml of a 2.5 M,
37.5 mmol solution in CH2Cl2, 10-3 M) was added
and the reaction vessel was shielded from ambient
lighting. After 1 hour, p-chloranil (2.8 g, 11.0
mmol) was added. The flask was immersed in a
water bath and the solution was refluxed for 1 hour.
The solution was then concentrated to
approximately 50 ml under reduced pressure, and
10-12 g of Florisil was added. The slurry was
further dried under reduced pressure to afford a
damp dark powder, which was poured onto the top
of a chromatography column (2.5 cm diameter)
filled with Florisil (38 cm in height). The column
was eluted with CH2Cl2/petroleum ether (3:1, 500
ml). The product was then eluted from the column
with CH2Cl2 (300-400 ml). The solvent was
removed under reduced pressure and a crystalline
purple solid was obtained. The yield was 2.1 g
(43%).
1H NMR (CDCl3). ppm 2.85 (br s, 2H, NH); 1.4-
3.2 (br s, 40H, B10H10); 4.12 (s, 4H, carborane CH);
4.48 (s, 8H, CH2); 7.26 (m, 4H, benz. ArH); 7.76
(m, 8H, benz. ArH); 7.93 (m, 4H, benz. ArH); 8.93
(s, 8H, pyr.ArH).
13C NMR (CDCl3).ppm 131.0 (meso-carbons);
143.1, 156.1 (benz.ArC-); 129.2, 128.1, 121.0,
114.2 (benz.ArCH); 69.6 (CH2O-Ar); 57.9 (RCH,
carborane); 71.4 (CR, carborane); 128.5 (pyr.
ArC-); 121.3 (pyr.ArCH).
11B (CDCl3).ppm 51.9, 50.0, 45.5, 43.0, 41.9.
UV-Vis. (CH2Cl2) max nm: 417, 513, 548, 590, 649.
Gadolinium-1, 6, 11, 16-tetra-[3-carboranyl-
methoxyphenyl]-porphyrin acetate. A 50-ml, three-
neck, round-bottomed flask fitted with a reflux
condenser and nitrogen inlet port was filled with 17
ml of distilled CH2Cl2. Tetra-carboranylmethoxy-
phenyl-porphyrin (0.20 g, 0.16 mmol) was added
and the solution was stirred magnetically for 10
minutes. To this solution, a Gadolinium (III) acetate
hydrate (0.050 g, 0.16 mmol) in methanol (2 ml)
was added and the reaction vessel was shielded
from ambient lighting. The flask was immersed in a
water bath and the solution was allowed to reflux
overnight. Insertion of gadolinium into the
porphyrin was monitored by UV-visible (Shimatzu,
UV-1601 PC) for completion. The solution was
evaporated to dryness under reduced pressure to
yield a purple crystalline solid, which was washed
with water (2  2 ml). The yield was 0.23 g (100
%).
Observed % Gd 10.6 Calculated % Gd (based
onGd(C56H76B40N4O4)(CH3CO2-) 10.4.
UV-Vis. (CH2Cl2) max nm: 424, 548, 588.
Sample preparation. Solutions of different MR
imaging contrast agents was prepared in the
following procedures:
Solutions of GdCl3, Gd-DTPA, and Gd-H were
prepared by accurately dissolving the required
amount in 0.9% saline solution.
Gd-TCP (15 mg, 0.010 mmol) was dissolved in 1
ml of cremophor EL (CRM) and 2 ml of 1,2-
propanediol. This solution was transferred into a 10
ml volumetric flask, and a 0.9% saline solution was
added to the mark. This gave a final concentration
of 1.0 mM.
Animal selection. The animal studies were
performed with nude mice (nu/nu, BALB/c) of 6-8
week old with a mean weight of 20 g (Animal
Resources, Western Australia). Animals were
randomly divided into five groups of six. Each
group was housed per cage in humidity and
temperature controlled, isolated animal house at St.
George Hospital, Sydney.
Tumor xenograft model.The human melanoma
cells, MM-138 (St. George Hospital, Sydney),
grown in tissue culture and originally derived from
human malignant melanoma, were injected (2.5
106 cells) subcutaneously in the both flanks of
nude mice.
Injected dose. Three to four weeks after tumor
implantation, when the tumor diameter was 3-5 mm
(mean weight of tumors was 200 mg), mice were
injected with different contrast agent conjugates.
All contrast agents were diluted in physiological
saline to a final concentration as injected in bolus
doses (10 mmol /kg of body weight). Two groups of
six mice were injected each intraperitoneally (i.p.)
with Gd-H and Gd-TCP. One group received Gd-
DTPA and the fourth group received GdCl3. The
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last group was a control group. The total injected
volume was 200 L. The animals were sacrificed by
an over-dose of pentobarbital sodium 24 h post i.p.
injection, followed by removal of critical organs
(tumor, kidney, liver, spleen). These organs were
minced for MR imaging and ICP-AES experiments
[7]. The gadolinium concentration in tumor and
various removed organs in in vivo measured using
acid digestion method by ICP-AES [8].
In vivo Proton relaxation times (T1)
determination. All MR imaging measurements and
spectra were obtained on a 300 MHz, 7.0 Tesla,
Varian UNITY Plus (Varian Associated, Inc., CA)
with a vertical Oxford Instruments magnet of bore
size 89 mm using the 15 mm saddle coil (DOTY
Scientific Instruments) resonator. The effect of
contrast agents on proton relaxation times was
measured in tumors and other organs using an
inversion recovery (IR) pulse sequence technique.
The T1 values and Gd concentration data for
different contrast agent solutions were used to
generate relaxivity rate constants, r1 in reciprocal
mmol seconds. This was accomplished via linear
regression analyses of 1/T1 versus Gd concentration
with r1 calculated as the slope of the fitted lines for
data collected different concentrations.
MR image signal intensity. The enhancement
effect of these agents on MR imaging signal was
investigated. All images were obtained using the T1-
weighted imaging method using IR pulse sequence
technique, with TE = 15 msec, TR = 300 msec, TI =
200 msec, 5 mm slice thickness, 3 3 cm2 field of
view, and matrix size of 256 128. The MR image
signal intensity was performed by selecting voxels
in the image transfer display. Five signal intensity
measurements were randomly obtained for each
voxel and an average of those was calculated as the
signal intensity.
Gd concentration measurements. All samples
(tissues) were frozen until used for ICP-AES
measurements. The gadolinium content was
measured based on an acid digestion procedure
using ICP-AES (Applied Research Laboratory, UK)
instrument according to the method of Tamat et al.
[8]. The 342.249 nm atomic emission line of Gd
was chosen for the ICP-AES analysis. The tissue
uptake of the Gd was calculated as a percentage of
the initial injected dose of contrast agent (% i.d.).
RESULTS AND DISCUSSION
Relaxivity. Specific targeting of MR imaging
contrast agents demands a detailed knowledge of
properties of the agent used. These details including
the feasibility and the required dose of injection as
well as uptake by the selected ligands. The efficacy
of porphyrin based contrast agents was calculated
by measuring their effect on proton relaxation
times. Therefore, a relaxivity measurement was
performed to detail investigation of the tissue-
specific contrast agents as shown in Table 1.
Relaxivity values of Gd-porphyrins are
approximately 4 or 5 times higher than Gd-DTPA.
This increase is due to its greater potential to
coordinate water molecules. These results are
consistent with reported relaxivity of porphyrin
based contrast agents [2].
Gadolinium concentration. The Gd tissue uptake
wascalculated as a percentage of the injected
contrast agent by organs and results are shown in
Table 2 and Figure 2. As can be seen from Figure 2,
for GdCl3 and Gd-DTPA the Gd uptake by the
tumor was 13% and 18%, respectively.
Tumor uptake of 21% and 28% of the injected
gadolinium was recorded for Gd-TCP and Gd-H,
respectively. This amount identified the potential of
the porphyrin-based compounds as tumor-specific
detection agents.Calculations of theconcentration
boron introduced into the tumor by Gd-TCP yield 24
.tg of boron concentrated into the cancer cells. This
amount is in agreement with the values for related
complexes studied by Miura el al. [6], is sufficient for
BNCT and proves the potential application of the Gd-
TCP in the dual roles as MR imaging agent and a
boron delivery agent for BNCT.
Table 1. Relaxivity values of gadolinium concentrations in
aqueous solutions of MR imaging contrast agents at room
temperature (23C).
Contrast agents r1 (mM-1 s-1) r2 (mM-1 s-1)
GdCl3 12.3  0.7 15.8  1.1
Gd-DTPA 3.7  0.1 4.8  0.2
Gd-H 16.3  1.4 20  1.6
Gd-TCP 31.7  0.3 38.2  0.6
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Fig. 1. (a) The schematic of synthesis of gadolinium-tetra-carboranylmethoxyphenyl-porphyrin and (b) the chemical
structure of Gd-H.
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Table 2. T1 relaxation times(s) of different organs of nude mice xenografted with human melanoma cell line. Tissues were
removed 24-h after injection of different contrast agents.
Compound/Sample Tumor Liver Kidney Spleen
GdC13 1.43 ± 0.03 0.74 ± 0.02 0.85 ± 0.01 0.84 ± 0.03
Gd-DTPA 1.37 ± 0.02 0.77 ± 0.01 0.87 ± 0.02 0.88 ± 0.02
Gd-TCP 1.33 ± 0.02 0.78 ± 0.02 0.94 ± 0.02 0.83 ± 0.02
Gd-H 1.26 ± 0.01 0.74 ± 0.02 0.98 ± 0.03 0.71 ± 0.03
Control 1.59 ± 0.03 0.96 ± 0.01 0.99 ± 0.04 0.96 ± 0.02
Data are mean ± SEM of values obtained from an average of five mice.
As indicated in Table 2, liver retained the highest
amount of gadolinium for both Gd-H and Gd-TCP.
At 24-h post-injection, the gadolinium content of
GdH and Gd-TCP was 34% and 32%, respectively.
This amount was at least 2 times greater in liver
than that of Gd-chelates. Some of the gadolinium
found in the liver might represent gadolinium
dissociated from the DTPA. It is known that free
gadolinium accumulates in the liver and this may
explain some of the high uptake in the
reticuloendothelial organ 18]. These data were
consistent with results of gadolinium content
observed in the liver for other porphyrin-based
agents [9]. Significant gadolinium accumulated in
the liver, spleen and kidney probably reflects
clearance and metabolism of the gadolinium
complexes [10]. The amount of boron concentrated
in the tumor by the uptake of Gd-TCP was 24 µg,
verifying its potential application for BNCT.
A small amount of gadolinium was observed in
the kidney at 24-h post injection. This is due to the
properties of gadolinium-based contrast agents,
which are hydrophilic and accumulated in the
extracellular water of tissues and have rapid renal
excretion [10].
T1 relaxation times. T1 values and standard
deviations were calculated by using an inversion
recovery pulse sequence. Table 2 shows the T1
measurements of organs using different contrast
agents and untreated mice (control).
The results showed T1 relaxation time of tumor
was significantly greater than that of normal
tissues. The general theory that T1 values are
longer in tumors was confirmed by this animal study.
This difference is reported to arise from an increase
in water content and the large extracellular volumes
of the cancerous tissues and these abnormalities
elevate the T1 values [11].
As Table 2 illustrated, for GdCl3, the T1
relaxation time was reduced approximately 10% in
the tumor compared to the control. For Gd-DTPA,
the modification of about 14% was observed in T1
values of the tumor. This standard clinical used
contrast agent showed a similar reduction of T,
relaxation time for both spleen and kidney. Both
porphyrin-based contrast agents, Gd-TCP and Gd-
H, showed a 16% and 21% decrease in the T1
value for the tumor, respectively.
The decreases in the T1 values of the contrast
agents were in line with the concentrations of
gadolinium absorbed by the tumors. These
reductions in the T1 relaxation times of the tumor
upon administration of contrast agent are highly
significant, even though this concentration of agents
used in this study (0.01 mmol/kg) is lower than the
doses of Gd-DTPA commonly used as a contrast
agent in clinical MR imaging (0.1 mmol/kg).
MR image signal intensity. The values of echo time
(TE = 15 ms) and repetition time (TR = 300 ms) were
optimized for the tumor of the control mice and were
used for all other tissue.
The graphs of MR image signal intensity for
removed organs and different contrast agents are
shown in Figure 3. In the control, the MR image
signal intensity for tumors was lower than that
recorded for the normal tissues under study. This
may result from the T1 relaxation time for the
tumor being longer than the other normal tissues,
which decreases MR image signal intensity and is
consistent with T1 values measured in this work
(Table 2).
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Fig. 2. Comparison of biodistribution of the gadolinium uptakes in melanoma grafted in nude mice for different compounds as MR
imaging contrast agent.
Fig. 3. MR image signal intensity imaging of tissues 24-h after injection of different gadolinium compounds (Data are mean ±
SEM of values obtained from an average of five mice).
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The highest MR image signal intensity (120%)
was observed for the tumor upon injection of Gd-H
over the control. After Gd-H, the other porphyrin-
based agent, Gd-TCP, showed good signal
enhancement (70%) over the control. The signal
enhancement of the porphyrin-based complexes in
this study is in good agreement with that of
reported previously by conjugation of Gd-DTPA
with porphyrins under in vivo conditions in mice
[12]. The results also showed the signal
enhancement of Gd-DTPA and GdC13 was
significant, but lower than those of porphyrin-
based contrast agents.
These results demonstrate the MR contrast
enhancing capabilities of Gd-TCP. This signal
enhancement of Gd-TCP accompanying with the
delivery of the number of boron atoms into the
tumors may be serve the dual use of the compound,
as it can enhance contrast between tumor and
normal tissues in MR images and be potentially
effective as an agent for BNCT.
The liver was the only organ that showed the
greatest enhancement for both porphyrin-based
agents and as stated previously, showed the
accumulation of gadolinium complex. In spite of
good accumulation of porphyrin-based agents into
the tumor, the accumulation of these agents in the
liver is problematic.
In conclusion, it is likely that tissue-specific
agents will be required for MR imaging of tumors
or lymph nodes. Methods using MR imaging and
porphyrinbased contrast agents could offer the
advantage of tissue contrast enhancement and
precise anatomic localization of the tumors.
Because of the ability of coordinate several water
molecules in aqueous solution, porphyrin-based
contrast agents showed higher relaxivity than that
of Gd-DTPA. These materials showed significant
enhancement effect in nude mice with melanoma.
Further developments in MR imaging contrast
agents, in combination with improved imaging
techniques, may lead to novel applications in the
diagnostic MR imaging. In this study, using Gd-
porphyrins and melanoma tumor xenograft model,
making possible quantitative studies of
paramagnetic contrast agent uptake.
These findings showed the possible application
of porphyrin-based contrast agents for the detection
of tumor, in particular for melanoma. The findings
also indicated that with the satisfactory Gd uptake
by the tumor and low levels in kidney and spleen
these agents are useful for tumor detection.
The outcome of this study may help the design of
tumor-specific contrast and chemotherapeutic
agents. The permeability of porphyrin-based
contrast agents may provide tissue uptake
information for both contrast and chemotherapeutic
agents. With current debate on tumor-specific and
therapeutic agents for tumor diagnosis and therapy,
the permeability of macromolecules to tumor
tissues is an essential question that needs to be
answered.
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